New drug duo takes on tough prostate cancers
NCT ID NCT07179783
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial is testing a combination of two drugs—sacituzumab tirumotecan and tagitanlimab—in people with aggressive variant or neuroendocrine prostate cancer that has progressed after prior treatments. The study aims to see if the combo can shrink tumors and delay disease progression. About 28 participants will receive the drugs intravenously every two weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- sacituzumab tirumotecan (SKB264) and tagitanlimab (KL-A167)
- What this could lead to
- If successful, this combination could offer a new treatment option for aggressive prostate cancers that have stopped responding to standard therapies.
- What could go wrong
- This is a small, early-phase trial with only 28 participants, so results may not apply broadly. The drugs may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA WITH NEUROENDOCRINE DIFFERENTIATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical Unversity Second Hospital
RECRUITINGTianjin, Tianjin Municipality, 300211, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A sharper eye on prostate cancer: could new imaging spare healthy tissue?
- Can a new drug combo tame resistant prostate cancer?
- Virtual cooking classes aim to boost health for hispanic prostate cancer survivors and their families
- Prostate Surgery's hidden toll: study probes lasting impact on Men's lives
- Which gas pump causes less pain during robotic prostate surgery? a Head-to-Head trial
- Nerve-Sparing radiation may help men keep sexual function after prostate cancer treatment